Friederike Kanefendt

628 total citations
21 papers, 455 citations indexed

About

Friederike Kanefendt is a scholar working on Genetics, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Friederike Kanefendt has authored 21 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 7 papers in Cardiology and Cardiovascular Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Friederike Kanefendt's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers), Mast cells and histamine (4 papers) and Renal cell carcinoma treatment (3 papers). Friederike Kanefendt is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers), Mast cells and histamine (4 papers) and Renal cell carcinoma treatment (3 papers). Friederike Kanefendt collaborates with scholars based in Germany, Italy and Denmark. Friederike Kanefendt's co-authors include Ulrich Jaehde, Andreas Lindauer, Uwe Fuhr, Matthias Scheffler, Oxana Doroshyenko, Jürgen Wolf, Stephan Schwers, Sigrun Unger, Ashraf Yassen and Dagmar Kubitza and has published in prestigious journals such as European Heart Journal, Clinical Pharmacology & Therapeutics and Clinical Pharmacokinetics.

In The Last Decade

Friederike Kanefendt

20 papers receiving 444 citations

Peers

Friederike Kanefendt

GENET

ONCOL

HEMAT

MB

CCM

Dalia El‐Gamal United States

Shigenori Kanazawa Japan

G Blaskó Hungary

Cecil Ross India

Eleanor Lisbon United States

José Padilla Spain

Takeshi Kadokura Japan

Rhonda Porche-Sorbet United States

Yasuhiro Sato Japan

Fukushi Hirayama Japan

Dalia El‐Gamal United States

Friederike Kanefendt

81 ×0.5

GENET

59 ×0.4

ONCOL

63 ×0.5

HEMAT

237 ×1.9

MB

82 ×0.9

CCM

Citations per year, relative to Friederike Kanefendt Friederike Kanefendt (= 1×) peers Dalia El‐Gamal

Countries citing papers authored by Friederike Kanefendt

Since Specialization

Citations

This map shows the geographic impact of Friederike Kanefendt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Friederike Kanefendt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Friederike Kanefendt more than expected).

Fields of papers citing papers by Friederike Kanefendt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Friederike Kanefendt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Friederike Kanefendt. The network helps show where Friederike Kanefendt may publish in the future.

Co-authorship network of co-authors of Friederike Kanefendt

This figure shows the co-authorship network connecting the top 25 collaborators of Friederike Kanefendt. A scholar is included among the top collaborators of Friederike Kanefendt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Friederike Kanefendt. Friederike Kanefendt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Kanefendt, Friederike, et al.. (2024). No Influence of Asundexian on Cardiac Repolarization. Clinical Pharmacology in Drug Development. 13(3). 265–280.

2.

Chen, Huijun, et al.. (2024). Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data. Clinical and Translational Science. 17(8). e13895–e13895. 3 indexed citations

3.

Sommer, Katharina, et al.. (2024). Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian. Clinical Pharmacokinetics. 63(11). 1631–1648. 1 indexed citations

4.

Piel, Isabel, Dieter Lang, Simone I. Schulz, et al.. (2023). Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans. European Journal of Drug Metabolism and Pharmacokinetics. 48(4). 411–425. 12 indexed citations

5.

Kanefendt, Friederike, et al.. (2023). Pharmacokinetics of asundexian with combined CYP3A and P‐gp inhibitors and an inducer: Target in vitro and in vivo studies. British Journal of Clinical Pharmacology. 90(4). 1036–1049. 5 indexed citations

6.

Kanefendt, Friederike, et al.. (2023). Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling. Clinical Pharmacology & Therapeutics. 115(5). 1025–1032. 7 indexed citations

7.

Kubitza, Dagmar, et al.. (2022). Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study. British Journal of Clinical Pharmacology. 88(7). 3447–3462. 43 indexed citations

8.

Kanefendt, Friederike, et al.. (2022). The complete bioavailability of asundexian is unaffected by tablet formulation, gastric pH or food. European Heart Journal. 43(Supplement_2). 3 indexed citations

9.

Kanefendt, Friederike, et al.. (2022). Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian. Clinical Pharmacology in Drug Development. 12(2). 219–230. 10 indexed citations

10.

Thomas, Dirk, et al.. (2021). First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. Journal of Thrombosis and Haemostasis. 19(10). 2407–2416. 59 indexed citations

11.

Zahger, Doron, Katia Orvin, Dan Admon, et al.. (2019). 87Effects of the chymase inhibitor fulacimstat on adverse cardiac remodelling after acute myocardial infarction - Results of the CHIARA MIA 2 trial. European Heart Journal. 40(Supplement_1). 1 indexed citations

12.

Kanefendt, Friederike, et al.. (2018). Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clinical Pharmacology in Drug Development. 8(4). 467–479. 18 indexed citations

13.

Düngen, Hans‐Dirk, Lars Køber, Savina Nodari, et al.. (2018). Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial. Clinical Pharmacology in Drug Development. 8(7). 942–951. 15 indexed citations

14.

Kanefendt, Friederike, JJ Swen, F. Sörgel, et al.. (2017). Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer. CPT Pharmacometrics & Systems Pharmacology. 6(9). 604–613. 19 indexed citations

15.

Mross, K., M. E. Scheulen, Dirk Strumberg, et al.. (2014). FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases â a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. International Journal of Clinical Pharmacology and Therapeutics. 52(8). 642–652. 6 indexed citations

16.

Kanefendt, Friederike, Andreas Lindauer, K. Mross, Uwe Fuhr, & Ulrich Jaehde. (2012). Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker. Journal of Pharmaceutical and Biomedical Analysis. 70. 485–491. 7 indexed citations

17.

Kanefendt, Friederike, Andreas Lindauer, Matthias Scheffler, et al.. (2011). Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics. 50(9). 551–603. 183 indexed citations

18.

Mross, K., Martin Büchert, Ulrike Fasol, et al.. (2011). A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment - a study of the CESAR central european society for anticancer drug research - EWIV**. 4 indexed citations

19.

Mross, K., Martin Büchert, Ulrike Fasol, et al.. (2011). A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.. PubMed. 49(1). 96–8. 6 indexed citations

20.

Lindauer, Andreas, Friederike Kanefendt, Dorota Tomalik‐Scharte, et al.. (2010). Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 87(5). 601–608. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact